C. Ronald Blankenship
Known title: DirectorCIK: 0001171118
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Civeo (CVEO) receives new analyst coverage and price targets. Roth Capital began coverage of Civeo and issued a $39 price target. Northland Capital also started coverage, assigning an Outperform rating and a $42 target. Both firms' reports add fresh analyst attention to the stock. The targets sit above the recent 52‑week high of $36.50, suggesting expectations of further upside.
Transaction History
| REG | ▲ Buy | Grant | 167 | — | 8/7/2026 | View on chart |
| CVEO | ▲ Buy | Grant | 3,624 | $0 | 5/27/2026 | View on chart |
| REG | ▲ Buy | Option Exercise | 1,875 | — | 5/11/2026 | View on chart |
| REG | ▲ Buy | Option Exercise | 77 | — | 5/11/2026 | View on chart |
| REG | ▲ Buy | Grant | 453 | — | 5/6/2026 | View on chart |
| REG | ▲ Buy | Grant | 481 | — | 2/4/2026 | View on chart |
| REG | ▲ Buy | Grant | 473 | — | 11/6/2025 | View on chart |
| REG | ▲ Buy | Grant | 479 | — | 8/8/2025 | View on chart |
| CVEO | ▲ Buy | Grant | 6,021 | $0 | 5/14/2025 | View on chart |
| REG | ▲ Buy | Option Exercise | 91 | — | 5/5/2025 | View on chart |
| REG | ▲ Buy | Grant | 481 | — | 5/5/2025 | View on chart |
| REG | ▲ Buy | Option Exercise | 2,284 | — | 5/5/2025 | View on chart |
| REG | ▲ Buy | Grant | 478 | — | 2/10/2025 | View on chart |
| REG | ▲ Buy | Grant | 506 | — | 11/12/2024 | View on chart |
| REG | ▲ Buy | Grant | 584 | — | 8/5/2024 | View on chart |
| CVEO | ▲ Buy | Grant | 5,051 | $0 | 5/15/2024 | View on chart |
| REG | ▲ Buy | Grant | 565 | — | 5/7/2024 | View on chart |
| REG | ▲ Buy | Option Exercise | 2,263 | — | 5/3/2024 | View on chart |
| REG | ▲ Buy | Option Exercise | 72 | — | 5/3/2024 | View on chart |
| REG | ▲ Buy | Grant | 566 | — | 2/12/2024 | View on chart |
| REG | ▲ Buy | Grant | 554 | — | 11/1/2023 | View on chart |
| REG | ▲ Buy | Grant | 588 | — | 8/1/2023 | View on chart |
| CVEO | ▲ Buy | Grant | 5,947 | $0 | 5/17/2023 | View on chart |
| REG | ▲ Buy | Grant | 556 | — | 5/4/2023 | View on chart |
| REG | ▲ Buy | Option Exercise | 85 | — | 5/3/2023 | View on chart |
| REG | ▲ Buy | Option Exercise | 1,962 | — | 5/3/2023 | View on chart |
| REG | ▲ Buy | Grant | 570 | — | 2/8/2023 | View on chart |
| REG | ▲ Buy | Grant | 572 | — | 11/3/2022 | View on chart |
| REG | ▲ Buy | Grant | 528 | — | 8/5/2022 | View on chart |
| CVEO | ▲ Buy | Grant | 4,879 | $0 | 5/18/2022 | View on chart |
| REG | ▲ Buy | Option Exercise | 2,158 | — | 5/9/2022 | View on chart |
| REG | ▲ Buy | Option Exercise | 77 | — | 5/9/2022 | View on chart |
| REG | ▲ Buy | Grant | 500 | — | 4/29/2022 | View on chart |
| REG | ▲ Buy | Grant | 485 | — | 2/11/2022 | View on chart |
| REG | ▲ Buy | Grant | 528 | — | 10/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Regency Centers Faces Analyst Adjustments Amid Rate Concerns
Regency Centers is navigating a challenging environment as broader REITs face pressure from high interest rates. Recent analyst actions include Truist assuming coverage at a Buy rating and Barclays lowering its price target to $85 while maintaining an Overweight stance. The company is also preparing for its third-quarter 2026 earnings call, with the stock currently trading near its 52-week low.
Regency Centers Faces Analyst Adjustments Amid Rate Concerns. Regency Centers is navigating a challenging environment as broader REITs face pressure from high interest rates. Recent analyst actions include Truist assuming coverage at a Buy rating and Barclays lowering its price target to $85 while maintaining an Overweight stance. The company is also preparing for its third-quarter 2026 earnings call, with the stock currently trading near its 52-week low.